Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down – Should You Sell?

Bicara Therapeutics Inc. (NASDAQ:BCAX) shares gapped down prior to trading on Friday . The stock had previously closed at $16.60, but opened at $16.01. Bicara Therapeutics shares last traded at $16.27, with a volume of 5,771 shares.

Analyst Ratings Changes

Several equities analysts have commented on the company. Cantor Fitzgerald started coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set an “overweight” rating for the company. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. Rodman & Renshaw assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating and a $48.00 target price for the company. Stifel Nicolaus initiated coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set a “buy” rating and a $47.00 target price for the company. Finally, TD Cowen started coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating on the stock. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $43.00.

Bicara Therapeutics Stock Performance

The company has a 50 day moving average of $20.81.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). As a group, equities analysts expect that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors have recently modified their holdings of BCAX. Cinctive Capital Management LP bought a new position in Bicara Therapeutics during the 3rd quarter valued at about $229,000. Barclays PLC bought a new position in Bicara Therapeutics during the third quarter valued at approximately $255,000. Jane Street Group LLC bought a new position in Bicara Therapeutics during the third quarter valued at approximately $309,000. Teachers Retirement System of The State of Kentucky purchased a new stake in Bicara Therapeutics in the third quarter worth approximately $358,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Bicara Therapeutics in the 3rd quarter worth approximately $462,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.